Aptevo Therapeutics Stock Book Value Per Share
| APVO Stock | USD 0.27 0.02 6.90% |
Aptevo Therapeutics fundamentals help investors to digest information that contributes to Aptevo Therapeutics' financial success or failures. It also enables traders to predict the movement of Aptevo Stock. The fundamental analysis module provides a way to measure Aptevo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aptevo Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 43.95 | 41.75 | |
| Tangible Book Value Per Share | 43.95 | 41.75 |
Aptevo | Book Value Per Share |
Aptevo Therapeutics Company Book Value Per Share Analysis
Aptevo Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Aptevo Therapeutics Book Value Per Share | 0.42 X |
Most of Aptevo Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aptevo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aptevo Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Aptevo Therapeutics is extremely important. It helps to project a fair market value of Aptevo Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Aptevo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aptevo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aptevo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Aptevo Book Value Per Share Historical Pattern
Today, most investors in Aptevo Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aptevo Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's book value per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Aptevo Therapeutics book value per share as a starting point in their analysis.
Aptevo Therapeutics Book Value Per Share |
| Timeline |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Aptevo Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Aptevo Therapeutics is about 0.419 times. This is 124.65% lower than that of the Biotechnology sector and 100.17% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.98% higher than that of the company.
Aptevo Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aptevo Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aptevo Therapeutics could also be used in its relative valuation, which is a method of valuing Aptevo Therapeutics by comparing valuation metrics of similar companies.Aptevo Therapeutics is currently under evaluation in book value per share category among its peers.
Aptevo Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aptevo Therapeutics from analyzing Aptevo Therapeutics' financial statements. These drivers represent accounts that assess Aptevo Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aptevo Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 26.7M | 124.3M | 36.9M | 11.9M | 2.2M | 2.1M | |
| Enterprise Value | 37.5M | 111.7M | 8.6M | (1.2M) | (9.3M) | (8.8M) |
Aptevo Fundamentals
| Return On Equity | -2.51 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 652.63 K | ||||
| Shares Outstanding | 13.44 M | ||||
| Shares Owned By Insiders | 0.03 % | ||||
| Shares Owned By Institutions | 10.50 % | ||||
| Number Of Shares Shorted | 1.2 M | ||||
| Price To Earning | 2.48 X | ||||
| Price To Book | 0.83 X | ||||
| Price To Sales | 1.61 X | ||||
| Gross Profit | 3.11 M | ||||
| EBITDA | (28.31 M) | ||||
| Net Income | (18.65 M) | ||||
| Cash And Equivalents | 29.43 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 5.4 M | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 4.48 X | ||||
| Book Value Per Share | 0.42 X | ||||
| Cash Flow From Operations | (11.73 M) | ||||
| Short Ratio | 0.09 X | ||||
| Earnings Per Share | (35.64) X | ||||
| Target Price | 9.25 | ||||
| Number Of Employees | 40 | ||||
| Beta | 5.07 | ||||
| Market Capitalization | 3.69 M | ||||
| Total Asset | 24.84 M | ||||
| Retained Earnings | (223.45 M) | ||||
| Working Capital | 11.84 M | ||||
| Current Asset | 71.41 M | ||||
| Current Liabilities | 19.54 M | ||||
| Net Asset | 24.84 M |
About Aptevo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aptevo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aptevo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aptevo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Aptevo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Aptevo Stock
Moving against Aptevo Stock
| 0.65 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.65 | DOMH | Dominari Holdings | PairCorr |
| 0.62 | DNLI | Denali Therapeutics Downward Rally | PairCorr |
| 0.46 | VCYT | Veracyte | PairCorr |
| 0.43 | VERA | Vera Therapeutics | PairCorr |
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Aptevo Therapeutics Piotroski F Score and Aptevo Therapeutics Altman Z Score analysis. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (35.64) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (2.51) |
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.